Literature DB >> 1950448

Psychotic complications of long-term levodopa treatment of Parkinson's disease.

A Friedman1, J Sienkiewicz.   

Abstract

The prevalence of psychotic complications of levodopa treatment was assessed in 198 Parkinson patients. The symptoms were seen in 44 (22.2%). Those who developed complications were significantly older at disease onset (63.3 +/- 9.2 vs 57.6 +/- 11.6). The observed psychiatric symptoms were classified into two categories: simple, including incidents of confusion alone or hallucinations with preserved insight, and complex, including delusions or chronic confusion without preserved insight. Patients with complex symptoms were significantly younger at the onset of the disease, and the duration of the disease prior to these psychiatric symptoms was longer than in the group of patients with simple symptomatology. Patients with complex symptoms were more susceptible to another central side-effect of the treatment: dyskinesias, than those with simple.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1950448     DOI: 10.1111/j.1600-0404.1991.tb04918.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

Review 1.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 2.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 3.  Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress.

Authors:  Anthony A Grace
Journal:  Neurotox Res       Date:  2010-02-09       Impact factor: 3.911

4.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

5.  Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

Authors:  David A M C van de Vijver; Raymund A C Roos; Paul A F Jansen; Arijan J Porsius; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2004-10

Review 6.  Psychiatric symptoms in Parkinson's disease.

Authors:  Karen E Anderson; William J Weiner
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 7.  Visual hallucinations in Parkinson's disease: a review and phenomenological survey.

Authors:  J Barnes; A S David
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

8.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 9.  Drug-induced cognitive impairment. Defining the problem and finding solutions.

Authors:  J D Bowen; E B Larson
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

10.  The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat.

Authors:  Emily R Hawken; Richard J Beninger
Journal:  Psychopharmacology (Berl)       Date:  2013-11-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.